

Special Issue

Carbapenem-Resistant *Acinetobacter baumannii*: From Molecular Mechanisms to Clinical Practice

Message from the Guest Editors

Acinetobacter baumannii has emerged as one of the most challenging multidrug-resistant pathogens in healthcare settings worldwide. In particular, carbapenem-resistant *A. baumannii* (CRAB) poses a serious threat due to its ability to acquire and disseminate resistance determinants, survive in harsh environments, and cause severe infections in vulnerable patients. The rise of CRAB has led to limited therapeutic options and increased morbidity and mortality, especially in intensive care units. This Special Issue aims at exploring CRAB from a multidisciplinary perspective, ranging from molecular resistance mechanisms, genomic surveillance, and epidemiology to infection control strategies, clinical management, and novel therapeutic approaches. We invite original research articles, reviews, and case reports, that contribute to a deeper understanding of CRAB and support evidence-based clinical practice.

Guest Editors

Prof. Dr. Antonio Cascio
Prof. Dr. David L. Paterson
Dr. Luca Pipitò

Deadline for manuscript submissions

closed (31 December 2025)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 10.2
Indexed in PubMed



mdpi.com/si/245093

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 10.2
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)